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Abstract
Background: Lipids are known to play crucial roles in the development of life-style related risk factors such as obesity,
dyslipoproteinemia, hypertension and diabetes. The first selective cannabinoid-1 receptor blocker rimonabant, an anorectic
anti-obesity drug, was frequently used in conjunction with diet and exercise for patients with a body mass index greater
than 30 kg/m
2 with associated risk factors such as type II diabetes and dyslipidaemia in the past. Less is known about the
impact of this drug on the regulation of lipid metabolism in plasma and liver in the early stage of obesity.
Methodology/Principal Findings: We designed a four-week parallel controlled intervention on apolipoprotein E3 Leiden
cholesteryl ester transfer protein (ApoE*3Leiden.CETP) transgenic mice with mild overweight and hypercholesterolemia. A
liquid chromatography–linear ion trap-Fourier transform ion cyclotron resonance-mass spectrometric approach was
employed to investigate plasma and liver lipid responses to the rimonabant intervention. Rimonabant was found to induce
a significant body weight loss (9.4%, p,0.05) and a significant plasma total cholesterol reduction (24%, p,0.05). Six plasma
and three liver lipids in ApoE*3Leiden.CETP transgenic mice were detected to most significantly respond to rimonabant
treatment. Distinct lipid patterns between the mice were observed for both plasma and liver samples in rimonabant
treatment vs. non-treated controls. This study successfully applied, for the first time, systems biology based lipidomics
approaches to evaluate treatment effects of rimonabant in the early stage of obesity.
Conclusion: The effects of rimonabant on lipid metabolism and body weight reduction in the early stage obesity were
shown to be moderate in ApoE*3Leiden.CETP mice on high-fat diet.
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Introduction
Obesity, a major risk factor for serious diet-related chronic
diseases such as diabetes and cardiovascular disease, is commonly
stated as critically important compositions of the metabolic
syndrome [1,2]. In recent decades, obesity has reached epidemic
proportions globally due to the rapid economic growth, modern-
ization and urbanization.Themajorcausesofitsrisingepidemicare
excessive consumption of energy-dense food high in saturated fats
and sugars and reduced physical activity [3,4]. Obesity is known to
be associated with dyslipoproteinemia characterized by increased
levels of plasma triacylglycerides (TG) and low density lipoprotein
cholesterol (LDL-C) and decreased level of high density lipoprotein
cholesterol (HDL-C) [5]. Chronic liver disease associated with
obesity has been identified in adults since 1970s and soon after this
condition was also reported in childhood and adolescence [6,7].
Most commonly, non-alcoholic fatty liver is observed in obese
subjects with liver disease. This disease is frequently caused by
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insulin action, leading to disordered metabolism of fat and free fatty
acids and subsequent oxidant mediated damage to the hepatocytes
[6].
Traditionally, prevention and treatment of obesity focus on
individual behavior interventions through increased regular
exercise and a low-fat, low refined carbohydrate diet [4]. It has
proven inadequate probably because the sociological factors are
not taken into account. Medical treatment approaches for obesity
have largely been developed in modern societies and appear to be
effective on the short term [8,9]. However, data reporting on long-
term health outcome based on successful treatment strategies are
very limited [10].
Previously, it has been demonstrated that early obesity is
associated with endothelial dysfunction in high-fat fed pigs [11].
The observed abnormalities such as mild dyslipidemia, vascular
oxidative stress and hypertension indicated that the early phases of
obesity play a key role in the progression of coronary atherosclerosis
and cardiovascular events and can be considered as the center point
of the metabolic syndrome [6,11–13]. Collectively, effective
strategies for prevention and recognition of overweight and obesity
in an early stage are critical.
Since lipids are involved in obesity-associated pathology, novel
tools that enable a large-scale study of individual lipids in biological
systems are highly demanded for understanding the potential
pathogenic mechanisms. Lipidomics technology can provide an
integrated view of lipid metabolites present in cells, tissues and
biological fluids[14–16].Thistool cannotonlyprovide insights into
the specific roles of lipids in monitoring health status, but will also
assist in identifying potential preventive or biomarkers [17,18]. The
availability of novel analytical and advanced instrumental as well as
powerful informatics technologies has facilitated the characteriza-
tion of global changes of lipids in metabolic conditions such as
obesity [19], insulin resistance [20], atherosclerosis [21], diabetes
[22], and hepatic steatosis [23] and has facilitated data integration
in order to understand the biological system.
Rimonabant, as the first selective cannabinoid-1 (CB1) receptor
blocker, was proved to lead to reduced food intake, long-term
maintained weight loss, and improved cardiovascular risk factors,
manifesting as elevated plasma HDL-C, reduced plasma TG and
inhibited insulin resistance in obese subjects [24–26]. In 2008 the
European Medicines Agency withdrew the drug from the market
in countries where it was commercially approved and marketed
because of the psychiatric side-effects (e.g. depression and even
suicide attempt) [27]. The aim of the current study was to unravel
the underlying effects of rimonabant on plasma and hepatic lipid
metabolism in the stage of early obesity.
For this we used a double transgenic mouse model, i.e.
apolipoprotein E3 Leiden cholesteryl ester transfer protein
(ApoE*3Leiden.CETP) transgenic mice, that matches with human
lipid metabolism as closely as possible. The presence of ApoE*3-
Leiden hampers the uptake of very low density lipoprotein (VLDL)-
remnants by the liver thus leading to increased VLDL/LDL-C
levels in the plasma. CETP is a plasma glycoprotein that is
responsible for the transportation of cholesterol ester (ChoE) from
HDL to apoB-containing lipoproteins (e.g. VLDL and LDL) in
exchange of TG, leading to decreased HDL-C levels [28,29]. This
gene is not present in wild type mice. Since in wild type mice the
plasma cholesterol (Cho) is almost completely confined to the HDL
fractionwhile VLDL and LDLarevirtuallyabsentduetothe lackof
CETP, wild type mice hardly develop dyslipidemia and, as a
consequence, atherosclerosis [30]. The ApoE*3Leiden.CETP mice,
however, have a higher VLDL/LDL-C level and relatively low
HDL-C level. Taken together, ApoE*3Leiden.CETP mice have a
human-like atherogenic lipoprotein profile. They not only respond
in a human-like manner to pharmaceutical interventions with
respect to lipid lowering efficacy [31,32] but also respond to HDL
modulating therapy. Many studies proved that the ApoE*3Lei-
den.CETP transgenic mouse is a valuable model to investigate the
pathogenesis of vascular atherosclerotic lesion development and the
effect of combination therapies on dyslipidemia and atherosclerosis
[33–38]. In this paper we reported the results of the study of large-
scale lipids in plasma and liver of 16 female ApoE*3Leiden.CETP
mice, 8 of which were subjected to a period of 4 weeks of
rimonabant intervention and 8 untreated animals.
Based on our study, we proposed that the rimonabant inte-
rvention on early obesity of ApoE*3Leiden.CETP mice would
affect plasma and hepatic lipid metabolism relative to the non-
treated controls, leading to increased HDL-C concentrations and
decreased VLDL/LDL-C levels.
Methods
Ethics statement
All animals received humane care conforming to the rules and
regulations set forward by the Netherlands Law on Animal
Experiments. All animal experiments were approved by an
independent institutional ethical committee on animal care and
experimentation (Dierexperimenten Commissie DEC of Nether-
lands Organization for Applied Scientific Research, Zeist, the
Netherlands) with a permit No. of DEC2489.
Animals
ApoE*3Leiden.CETP transgenic mice, expressing a human
CETP gene [34], were bred at TNO (Leiden, the Netherlands). In
this study, sixteen female ApoE*3Leiden.CETP mice were used.
All mice were housed under standard conditions in conventional
cages (4 mice per cage) with free access to water and food. At the
age of 6–10 weeks, mice were fed a semi-synthetic modified
Western-type diet (Hope Farms, Woerden, Netherlands) contain-
ing 15% (w/w) saturated fat, 0.2% (w/w) Cho and 40% (w/w)
sucrose as described by Nishina et al [39] as a 4 weeks run-in diet
in order to get mildly elevated lipid levels (plasma Cho levels of
about 14–18 mmol/L) and a moderate increase in body weight.
Thereafter (t=week 0), mice were matched on body weight and
plasma Cho and TG levels (after 4 h fasting) and separated into 2
groups. Subsequently, mice received a Western-type diet (Hope
Farms, Woerden, Netherlands) without or with rimonabant
(Sanofi-Aventis Netherlands B.V., Gouda, The Netherlands) at a
concentration of 10 mg/kg body weight/day for a period of 4
weeks.
Table 1 presents the study design and time points at which both
biochemical parameter and lipidomics profiling measurements
were done.
Sacrifice and Sample Collection
Animals were sacrificed with rapid asphyxiation with CO2 and
opened longitudinally after 4-week intervention experiment. Blood
was collected before start of the intervention (t=week 0) and just
before sacrifice (t=week 4) via tail vein bleeding into CB 300 LH
microvettes (Sarstedt, Nu ¨mbrecht, Germany), containing lithium
heparin and were placed on ice immediately after blood collection.
Plasma samples were obtained after centrifugation of the blood
samples for 10 min at 6000 rpm at 4uC. Liver tissues were
dissected on ice and immediately weighted before being snap-
frozen in liquid nitrogen. Both the plasma and the tissue samples
were stored at 280uC until use.
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Plasma samples collected at t=week 0 and t=week 4 were
assayedfortotalcholesterol(TC),total triacylglycerides (TG),HDL-
C and lipoproteinprofile.PlasmaTCand TG were quantifiedusing
the commercially available enzymatic kits 236691 and 11488872
(Roche Molecular Biochemicals, Indianapolic, IN, USA), respec-
tively. Plasma HDL-C was quantified after precipitation of apoB-
containing lipoproteins. Pooled lipoprotein profiles were measured
byfastperformanceliquid chromatography(FPLC)usinganAKTA
apparatus(AmershamBiosciences).Cho,TGandPhospholipid(PL)
levels were measured in the fractions of freshly obtained samples.
PLsweredeterminedintheFPLC fractionsusingkit‘‘phospholipids
B’’ (Instruchemie Co., The Netherlands).
Measurement of cholesteryl ester transfer activity in
plasma
CETP level was measured in each animal using the enzymatic
kit ‘‘RB-CETP’’ (Roar Biomedical, Inc.). The transfer of newly
synthesized ChoE in plasma was assayed by a radioisotope method
as described before [40]. Briefly, [
3H] Cho mixed with bovine
serine albumin was equilibrated with plasma free Cho for 24 h at
4uC followed by incubation for 3 h at 37uC. Subsequently, apoB-
containing lipoproteins were precipitated by addition of heparin/
MnCl2. Lipids were extracted from the precipitation and the
labeled cholesteryl esters were separated from labeled unesterified
Cho on silica columns and assayed by liquid scintillation counting.
Lipidomics analyses
Lipid extraction for plasma samples. Briefly, 30 mlo f
internal standard (IS) mixture containing lyso-phosphocholine
LPC (17:0) at 1.5 mg/ml, phosphatidylethanolamine PE (34:0) at
5 mg/ml, phosphatidylcholine PC (34:0) at 5 mg/ml and TG (51:0)
at 5 mg/ml in 2:1 of dichloromethane (CH2Cl2)/methanol
(MeOH) and 30 ml of IS mixture containing LPC (19:0) at
30 mg/ml, PE (30:0) at 30 mg/ml, PC (38:0) at 150 mg/ml and TG
(45:0) at 60 mg/ml in 2:1 of CH2Cl2/MeOH were added to 30 ml
of plasma which was placed in a new 2 ml eppendorf vial
(Eppendorf, Hamburg, Germany). Following this, 180 ml MeOH
and 360 mlC H 2Cl2 were successively added. Thorough vortex was
performed both before and after CH2Cl2 addition. Subsequently,
120 ml water was added to form a two-phase system in which lipids
were located in the bottom organic phase. After 10 min
centrifugation at a rotation speed of 6000 g at 10uC, 300 mlo f
lipid extracts from the bottom layer were transferred into a new
brown auto-sampler vial. The extracts were diluted 20 times with
acetonitrile/isopropanol/water (13:6:1, v/v/v) before LC–MS
running.
Lipid extraction for liver samples. Sixty microliters of IS
mixture containing LPC (17:0) at 1.5 mg/ml, PE (34:0) at 7.5 mg/
ml, PC (34:0) at 12.5 mg/ml and TG (51:0) at 45 mg/ml in 2:1 of
CH2Cl2/MeOH and 60 ml of IS mixture containing LPC (19:0) at
18 mg/ml, PE (30:0) at 90 mg/ml, PC (38:0) at 150 mg/ml and TG
(45:0) at 480 mg/ml in 2:1 of CH2Cl2/MeOH were added to
10 mg of dry liver powder followed by addition of 160 mlo f
MeOH containing 0.02% antioxidant butylated hydroxytoluene,
and then 320 mlo fC H 2Cl2 was added. The mixture was
thoroughly vortexed for 1 min both before and after CH2Cl2
addition. After that, the resulted suspension was placed for 5 min
in an ultrasonic bath at 24uC and then placed in a shaker
followed by 45 min incessantly shaking at 24uC. A 10 min
centrifugation at a rotation speed of 6000 g at 10uC was needed
before 500 ml of the supernatant was transferred into a new 2 ml
eppendorf vial. Subsequently, 100 ml of 0.9% NaCl was added to
the supernatant to give rise to a two-phase system: the nonlipid
compounds were located in the upper aqueous phase, while most
of the lipids were in the lower organic phase. After being
centrifuged at 2000 g for 10 min at 10uC, a total of 300 ml of lipid
extract was collected from the bottom organic phase. Diluted the
lipid extracts 406with acetonitrile/isopropanol/water (13:6:1, v/
v/v); 10 ml was loaded for LC–MS lipidomics analysis.
LC–MS lipid profiling. Diluted lipid extracts from both
plasma and liver tissue samples were measured on a liquid
chromatography–linear ion trap-Fourier transform ion cyclotron
resonance-mass spectrometric (LC–FTMS) system equipped with
a Surveyor HPLC MS pump, an autosampler (Thermo Fischer,
San Jose, CA) and an Ascentis Express C8 2.16150 mm (2.7 mm
particle size) column (Sigma-Aldrich Chemie B.V., Zwijndrecht,
The Netherlands). The binary solvent consisted of water/
acetonitrile (2:3, 10 mM ammonium formate) and acetonitrile/
isopropanol (1:9, 10 mM ammonium formate). The LC separation
conditions were identical to those described previously [41]. The
lipidomics profiling was carried out in the full ESI positive ion
mode with a mass range of m/z 430–1500. The heated capillary
was set at 300uC. The voltages of the sampling cone and capillary
Table 1. Study design and time points at which both biological parameters and lipidomic profiling were done.
Time points of experiment (week) 24 23 22 21 0 1234
Run-in period Intervention
period
Group 1, control 6 R 6 R 6
Group 2, rimonabant treatment 6 R 6 R 6
Randomization 6
Body weight and food intake 66666
Plasma cholesterol and triacylglyceride 66
Lipoprotein profile 66
HDL-C measurement 66
CETP level & activity 66
Sacrifice with plasma & liver collection for lipidomics 6
doi:10.1371/journal.pone.0019423.t001
Plasma and Liver Lipidomics in Transgenic Mice
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19423were 3.8 kV and 48 V, respectively. The tube lens was optimized
to be 140 V. Nitrogen was used as sheath gas (60 units), auxiliary
gas (5 units) and sweep gas (3 units). The LC–MS data were
acquired by Xcalibur (Thermo Fisher) with 200 ms maximum
injection time. The number of mscans was 2. Both the ion trap and
FT scan events were recorded during data acquisition.
Specifically, samples of interest (i.e. plasma or liver samples)
were randomly analyzed and the quality control (QC) samples,
prepared by pooling of all plasma or liver samples, were regularly
placed in the measurement sequence. Of note, plasma and liver
samples were analyzed separately. General information of 8
exogenous lipid standards used for lipidomics analyses were
summarized in the Supporting Information Table S1. The spiked
concentrations of 8 exogenous lipid standards used in lipidomics
analyses and normalization strategies used for LC–MS lipidomics
data analyses were summarized in the Supporting Information
Table S2.
Preprocessing of lipidomics data. Lipid peaks including
spiked IS such as LPC (17:0), LPC (19:0), PE (34:0), PE (30:0), PC
(34:0), PC (38:0), TG (51:0) and TG (45:0) were extracted based on
their expected retention time and accurate masses according to an
in-house lipid database using LCquan v2.5 (Thermo Fisher). The
peak area of each extracted lipid ion was calibrated by an
appropriate IS. Duplicate measurements were averaged to a single
measurement after IS calibration. Data quality was assessed by
calculating the relative standard deviation (RSD) of all calibrated
lipid peaks in the QC samples. Peaks with a RSD larger than 20%
were excluded leaving 131 lipids in the plasma lipidomics data set
and 133 lipids in the liver lipidomics data set for subsequent data
analyses (see the Supporting Information Table S3).
General lipidomics protocol and lipidomics platform character-
istics such as linearity, repeatability and recovery were provided in
the Supporting Information Text S1, Figures S1, S2, S3 and
Tables S4, S5, S6, S7, S8.
Statistical analysis
Statistical significance of biochemical parameters was analyzed
by independent student t-test. Lipidomics data were first analyzed
by independent student t-test and later extended with Benjamini
and Hochberg multiple testing corrections. Data were expressed as
mean 6 SD unless otherwise stated. A value of p,0.05 was
considered statistically significant.
In order to visualize possible relations between the samples from
treated and non-treated groups, principal component analysis
(PCA) was carried out for the mean centered plus unit variance
scaled plasma lipidomics data and liver lipidomics data, respec-
tively using Matlab software (version 6.5.1, release 13, The
Mathworks, 2003).
One control mouse (marked as 3733) was excluded from
statistical data analyses, because it did not respond to Western-
type diet during run-in period and failed to reach hypercholes-
terolemia criteria essential for our experiment. We observed that
the relative levels of most hepatic lipids were much lower in this
mouse as compared to the other control mice. In this animal, the
biochemical markers such as plasma TC, TG and liver weight
were lowest among all control mice (data not shown).
Figure 1. Food intake and body weight. The 4-week intervention effect of rimonabant on food intake and body weight was evaluated by
measuring body weight (per mouse) and food intake (per cage) of the rimonbant and nontreated control mice at day 0, 2, 3, 4, 9, 11, 14, 21 and 28
respectively. (A) Food intake. (B) Body weight. Values are expressed as means 6 SD; * p,0.05 vs. the control.
doi:10.1371/journal.pone.0019423.g001
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Food intake and body weight
The variation in food intake and body weight during the 4
weeks of intervention is shown in Figure 1A and B, respectively.
The body weight was significantly reduced in mice on rimonabant
compared to control throughout the whole intervention period. In
total, the weight loss was 9.4% (p=0.03) at the end of the
experiment. This decline in body weight might be explained by
reduced food intake in the initial states of the experiment, although
statistical significance was not reached.
Plasma cholesterol, triacylglycerides, HDL-C and plasma
lipoprotein profiles
After a period of 4 weeks of intervention, plasma TC was signif-
icantly reduced by 24% (p=0.04) (Figure 2A) and plasma TG reached
a reduction trend (e.g. 1.3460.96 vs. 2.3561.34 mM, p=0.11) in the
rimonabant group as compared to the control mice (Figure 2B). As
Figure 2. Plasma cholesterol, triacylglycerides, HDL-C and plasma lipoprotein profiles. Plasma concentrations are shown for TC (A), TG (B)
and HDL-C (C) of the rimonabant and nontreated mice at week 0 and 4. Values are shown as means 6 SD; * p,0.05 vs. the control. Alterations of Cho
(D) and TG (E) as well as PLs (F) in the pooled lipoprotein profiles of the rimonabant treatment group and the controls (t=week 4). Fractions 4–7
represent VLDL; fractions 8–9 represent intermediate-density lipoprotein (IDL); fractions 10–15 represent LDL; fractions 16–23 represent HDL.
doi:10.1371/journal.pone.0019423.g002
Figure 3. Rimonabant does not significantly affect plasma CETP activity. Effect of rimonabant on plasma CETP was evaluated by CETP
protein level (A) and CETP activity (B) in ApoE*3Leiden.CETP mice at t=week 0 and 4 (white bars: the control group; black bars: the rimonabant
group). Values are means 6 SD. There were no statistically significant changes found in either CETP or CETP activity during the intervention
treatment.
doi:10.1371/journal.pone.0019423.g003
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plasma HDL-C upon rimonabant intervention (Figure 2C).
The 4-week rimonabant intervention led to decreased levels of
Cho, TG and PLs in the VLDL for 1.5, 2.5 and 2 fold respectively
(Figure 2D–F) and to a slightly increased level of Cho in HDL
particles (magnified part in Figure 2D). Concentrations for Cho
and TG as well as PLs were unaffected in LDL particles, whereas
TG and PL concentrations were unaffected in HDL particles.
Rimonabant does not significantly affect plasma CETP
activity
The CETP level was constant during the intervention
(Figure 3A). The four-week rimonabant intervention resulted in
a non-significant change of plasma CETP activity (e.g. 90.8627.0
vs. 70.6633.3 nmol/ml/h, p=0.22) as compared to the control
(Figure 3B).
Lipidomics reveals differences between non-treated and
rimonabant-treated mice for both plasma and liver samples
Togetanoverviewofexistingpatternsinthe lipidomicsdatasuch
as clusters of mice of nontreated controls and mice undergoing
rimonabant treatment and which lipids contributed most to these
clusters, we performed PCA for the plasma and liver lipidomics
datasets, respectively. Figure 4 displays the PCA biplots (A, plasma
samples; B, liver samples). In both plasma and liver the rimonabant
treated group was separated well from the control group. Two
Figure 4. Lipidomics reveals differences between non-treated and rimonabant-treated mice for both plasma and liver samples.
Principle component analyses (PCA) of plasma and liver lipidomics data were applied to differentiate the nontreated controls (n=7) and the animals
treated with rimonabant (n=8) in plasma and liver samples, respectively. PCA biplots for the first two principal components of lipid profiling of
plasma samples (A) and liver samples (B). Both PCA models used mean centred plus unit variance scaled data.
doi:10.1371/journal.pone.0019423.g004
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the others within the group causing some overlap with the mice
from the control liver group. The deviations of these two mice from
other group members were further checked with data from
biological parameters and lipidomics. The biological parameters
revealed thatamongallrimonabant treated micetheliverweights of
these two mice were the heaviest and the total plasma TG levels
were the lowest (data not shown). The liver lipidomics data showed
that the TGlevelsweremore abundantinthesetwomicethanother
rimonabant treated mice. In addition, the loadings in the biplot
(lipid species represented by colored symbols in Figure 4A and B)
indicated that TG lipid species dominated the differentiation
between non-treated controls and the rimonabant-treated mice for
both plasma and liver lipidomics data sets.
Rimonabant significantly affects individual lipids in both
plasma and liver of treated mice
In order to investigate quantitative changes of lipids in the
rimonabant intervention group as compared to the control, statistical
significance for the mean difference of all identified lipids between the
Table 2. Lipid molecular species significantly changed in plasma of ApoE*3Leiden.CETP mice upon the rimonabant treatment as
compared to the untreated controls.
Rimonabant
Lipid species Control Rimonabant vs. control Up (q)o r
(mean ± SD) (mean ± SD) change (%) p value down (Q)
LPC (18:1) 0.289660.0146 0.241460.032 83 0.0030** Q
LPC (18:2) 0.140260.0105 0.106960.0138 76 0.0002*** Q
LPC (20:3) 0.026460.0023 0.021960.0034 83 0.0109* Q
LPE (20:4) 0.002260.0001 0.001760.0002 76 0.0001*** Q
PC (36:2) 0.084860.0088 0.073860.0059 87 0.0133* Q
PC (38:2) 0.506760.0589 0.377360.0624 74 0.0012** Q
PE (36:3) 0.757360.1050 0.608760.1137 80 0.0214* Q
PE (38:2) 0.267860.0457 0.204260.0205 76 0.0035** Q
PE (38:4) 0.145360.0243 0.112660.0146 77 0.0068** Q
SPM (16:0) 0.004660.0003 0.005460.0004 118 0.0006*** q
SPM (18:0) 0.000860.0001 0.001060.0001 122 0.0102* q
ChoE (18:1) 0.118760.0171 0.091760.0210 77 0.0180* Q
TG (44:0) 0.016960.0009 0.015160.002 89 0.0437* Q
TG (46:0) 0.032860.0037 0.027360.0047 83 0.0259* Q
TG (46:1) 0.012760.0038 0.007860.0033 62 0.0198* Q
TG (48:0) 0.016760.0057 0.00960.0056 54 0.0202* Q
TG (48:1) 0.008460.0028 0.004860.0032 57 0.0387* Q
TG (48:2) 0.103760.0302 0.055860.0411 54 0.0247* Q
TG (50:0) 0.049360.0196 0.025160.0197 51 0.0329* Q
TG (50:1) 0.156860.0685 0.080560.0631 51 0.0429* Q
TG (52:2) 1.030460.4185 0.524860.4136 51 0.0353* Q
TG (52:6) 0.002560.0008 0.001360.001 52 0.0298* Q
TG (54:2) 0.318960.1698 0.150860.1247 47 0.0459* Q
TG (54:3) 0.916060.3800 0.456860.3700 50 0.0341* Q
TG (54:4) 0.178060.0750 0.092160.0693 52 0.0382* Q
TG (56:3) 0.100160.0481 0.045360.0314 45 0.0200* Q
TG (56:4) 0.076560.0328 0.039660.0253 52 0.0289* Q
TG (56:7) 0.374960.1634 0.205560.134 55 0.0459* Q
TG (58:3) 0.005760.0028 0.002960.0017 52 0.0367* Q
TG (58:4) 0.005160.0022 0.002860.0014 55 0.0290* Q
TG (58:5) 0.015560.0069 0.008460.005 54 0.0384* Q
TG (58:6) 0.016260.0055 0.009860.0044 60 0.0253* Q
TG (58:7) 0.026460.0091 0.01660.0078 60 0.0322* Q
*P,0.05,
**p,0.01,
***p,0.001 vs. the untreated controls.
P values correspond to the mean difference between the rimonabant treatment and the untreated controls.
Note: lipids with p values marked in bold mean those remain significant after multiple testing correction.
doi:10.1371/journal.pone.0019423.t002
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lipid species out of 131 and 133 lipids respectively were significantly
changed after the 4-week rimonabant intervention as compared to the
controls.Four lipids changed significantlyupon rimonabant treatment
in both plasma and liver, i.e. PE (36:3), TG (50:1), TG (52:2) and TG
(56:7). Within these perturbed lipids, one interesting observation was
that 31 out of 33 lipid species were significantly decreased in plasma
whereas 22 out of 25 lipid species were significantly increased in liver in
the rimonabant group versus the controls (Table 2 and 3).
Remarkably, after multiple testing correction only 6 plasmalipids
(LPC-18:1, LPC-18:2, LPE-20:4, PC-38:2, PE-38:2 and sphingo-
myelin SPM-16:0) and 3 liver lipids (PC-40:4, ChoE-16:1 and TG-
56:6) remained significant out of 33 and 25 plasma and liver lipids
respectively (lipids with p values marked in bold in Table 2 and 3).
Rimonabant significantly decreases the overall responses
of plasma lipid classes
The summation of the individually measured lipids into
different lipid classes in plasma showed a significant reduction
of PE with 20% (p=0.02), ChoE with 22% (p=0.02) and TG
with 46% (p=0.04) in rimonabant treated mice vs. the control
(white bar graph in Figure 5); the summation of individually
measured lipids into lipid classes of LPC, PC and SPM in plasma
of mice receiving rimonabant treatment were comparable to
those in untreated controls under the current LC–MS conditions.
In total, the level of PLs in plasma samples was comparable in
rimonabant treated mice vs. the control (data not shown). In liver
tissues, none of the summation of the individually measured lipids
within each of lipid classes was significantly changed after the
rimonabant intervention in relation to the control (black bar
graph in Figure 5).
Discussion
Rimonabant, a selective CB1 receptor antagonist, is known for
reducing body weight and improving cardiovascular risk factors in
obese subjects [24,25,42–44]. However, studies of the obesity
regulation effects of rimonabant mainly focus on the plasma/
serum biochemical and lipid profile [45–47]. Less is known about
Table 3. Lipid molecular species significantly changed in liver of ApoE*3Leiden.CETP mice upon the rimonabant treatment as
compared to the untreated controls.
Rimonabant
Lipid species Control Rimonabant vs. control Up (q)o r
(mean ± SD) (mean ± SD) change (%) p value down (Q)
PC (38:4) 2.16060.299 2.56360.319 119 0.0262* q
PC (40:4) 0.15760.012 0.19660.024 125 0.0018** q
PC (40:5) 0.83460.069 1.05260.184 126 0.0113* q
PC (40:6) 0.54660.048 0.66860.086 122 0.0054** q
PC (40:8) 0.27260.040 0.22560.036 83 0.0318* Q
PE (34:1) 0.25460.038 0.30860.055 121 0.0484* q
PE (36:3) 0.52960.126 0.41860.066 79 0.0493* Q
PE (38:6) 1.47460.079 1.78560.341 121 0.0355* q
PE (40:6) 0.56360.057 0.71160.125 126 0.0133* q
ChoE (16:1) 0.62860.232 1.07860.160 172 0.0007*** q
ChoE (22:6) 0.04360.008 0.05460.005 127 0.0054** q
TG (50:1) 1.35760.363 1.77360.362 131 0.0450* q
TG (50:2) 1.77960.570 2.49760.636 140 0.0396* q
TG (50:3) 0.34760.132 0.58160.211 167 0.0251* q
TG (52:2) 7.23461.170 8.57261.160 118 0.0448* q
TG (52:4) 0.46260.116 0.67960.229 147 0.0411* q
TG (52:5) 0.52660.165 0.84060.346 160 0.0478* q
TG (54:5) 0.35460.078 0.50460.136 143 0.0235* q
TG (54:6) 0.61660.181 1.02160.305 166 0.0091** q
TG (54:7) 0.07860.025 0.14160.058 180 0.0195* q
TG (56:5) 0.51760.100 0.68760.151 133 0.0250* q
TG (56:6) 0.13560.027 0.20960.033 155 0.0005*** q
TG (56:7) 1.04760.281 1.56260.558 149 0.0461* q
TG (56:8) 0.16860.049 0.27460.108 163 0.0326* q
TG (60:1) 0.01560.002 0.01260.002 83 0.0352* Q
*P,0.05,
**p,0.01,
***p,0.001 vs. the untreated controls.
P values correspond to the mean difference between the rimonabant treatment and the untreated controls.
Note: lipids with p values marked in bold mean those remain significant after multiple testing correction.
doi:10.1371/journal.pone.0019423.t003
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rimonabant treatment in obese subjects.
The present study describes the rearrangement and relocalisation
of lipids in an early obese ApoE*3Leiden.CETP mouse model with
humanized lipoprotein metabolism exposed to a 4-week rimona-
bant intervention. Lipoprotein profiling and lipidomics approaches
were used for this purpose.
Throughout the experiment, food intake upon rimonabant
dropped sharply during the first two days but quickly recovered to
some extent during the first 3 weeks; since day 21, food intake has
returned to nearly the levels in identical high-fat fed mice without
rimonabant treatment. In spite of the recovery of energy intake
within 3 weeks, the rimonabant group exhibited a significant and
maintained weight reduction throughout the intervention period as
compared with the non-treated controls. Collectively, this body
weight reduction may be attributed to 1) the transient reduction in
energy intake; 2) a reduction in energy efficiency (i.e. wastage of
energy) caused by interruption of cannabinoid signalling upon
rimonabant treatment [48]. Notably, the 9.4% body weight
reduction induced by rimonabant treatment in our study seems
nottobecomparablewith the atleast20%bodyweightlossinduced
by rimonabant reported in literature for obese mice or humans
[42,43]. However, it should not be neglected that the mouse model
used in our study was in the early stage of obesity with only mildly
increased body weight and plasma Cho.
Rimonabant intervention studies both in rodents and humans
[24,25,46,47,49] have shown significant reduction of plasma TC
andTGandasignificantincreaseinHDL-Cconcentrations.Our4-
week rimonabant treatment of ApoE*3Leiden.CETP transgenic
mice in early stage of obesity showed similar reduction of plasma
TC and a reduction trend of plasma TG. However, the treatment
did not significantly increase levels of HDL-C, which was probably
dueto our short interventionperiodcombined withan early stage of
obesity in our animal model. In line with these observations, plasma
Cho and TG in VLDL were reduced, whereas Cho in HDL was
slightly increased after the rimonabant intervention. These effects
may be mediated via adiponectin, a major adipocyte cytokine
involved in the regulation of hyperglycaemia, hyperinsulinaemia,
and fatty acid oxidationat the peripheraladipocyte level [44,50,51].
Adiponectin release from adipocytes is known to be regulated by
inhibition of CB1 [43,52]. Furthermore, no significant reduction
effect of rimonabant on CETP activity or levels was found in the
ApoE*3Leiden mouse model.
The LC–MS-based plasma lipidomics analysis revealed a
significant decrease of a large number of plasma lipids and a
significant reduction in plasma PE, ChoE and TG lipid classes after
rimonabant intervention, indicating the beneficial effect of
rimonabant on plasma lipid metabolism in early stage of obesity.
Specifically, as ChoE, TG and PLs (e.g. PE) are the main
components of VLDL particles, their reduction in plasma indicated
a lower circulated VLDL induced by rimonabant, which is in line
with the result of plasma lipoprotein profiles, i.e., the VLDL
fractions of Cho, TG and PLs were all reduced in rimonabant
group. Evidence from animal studies and clinical trials indicated
that the beneficial metabolic effects of rimonabant on plasma/
serum lipid profiles are caused by the absence of basal endocanna-
binoid signaling, leading to reduced energy efficiency of food
[24,48,53]. In addition, after multiple testing corrections six plasma
lipid species showed a most significant reduction in response to
rimonabant except for SPM (16:0) which increased. Although it is
unknown if these lipid compounds would be useful for understand-
ing the pharmacological manipulation of rimonabant on improving
obesity-related metabolic abnormalities under current experimental
conditions, it may point to an important role of individual lipid
molecular species in rimonabant’s influence on the management of
obesity.
It is recognized that high-fat diet-induced obesity is highly
associated with a fatty liver due to the expression of the hepatic CB1
receptor [49,54]. Liver-specific deletion of CB1 or blockage of the
CB1 receptor was frequently used to protect against obesity-
associated hepatic steatosis [47,49,53]. The results from available
studies suggest that rimonabant, as a CB1 receptor antagonist,
potentially has clinical applications in the treatment of high-fat diet-
inducedliverdiseases[47,53]. Inthepresentstudy,down-regulation
of lipids was not observed in liver tissues as it is in plasma after
rimonabant treatment. This could be due to the early stage of
obesity in our animal model, which displays a mild increase in body
weight and moderately elevated plasma Cho levels (14–18 mmol/
L). It also needs to be noted that our animal model is very different
from those used in literature to investigate rimonabant’s manage-
ment in high-fat diet-induced liver disease. Our ApoE*3Leiden.-
CETP mice express a natural mutation of the human APOE3 gene
in addition to the human APOC1 gene. Introduction of these genes
induces an attenuated clearance of apoB-containing lipoproteins via
the LDL receptor pathway [34,55]. Mice with such a genetic
background show mildly increased Cho and TG levels on a chow
diet and a human-like lipoprotein profiles on high fat diet [56]. In
summary, we proposed that 4-week rimonabant treatment has
a moderate effect on liver lipid metabolism in the early stage of
obesity of ApoE*3Leiden.CETP mice under current experimental
conditions.
This study shows that LC–MS lipidomics approaches is
promising for discovery of lipid biomarkers in relation to disease
prevention and health promotion. Moreover, it was demonstrated
that a 4-week rimonabant intervention improves body weight and
cardiovascular risk factors during the early stage of obesity in
ApoE*3Leiden.CETP mice. Finding of only limited amount of
significant lipid changes may be attributed to the early stage of
obesity in the animal model used. Taken together, it indicates that
the effects of rimonabant on body weight and cardiovascular risk
factors are moderate in the case of early stage obesity.
Figure 5. Rimonabant significantly decreases the overall
responses of plasma lipid classes. Relative change of the
summation of the individually measured lipids in different lipid classes
was determined based on plasma and liver lipidomics data of the
rimonabant group and the controls (white bars: plasma samples; black
bars: liver samples). The summation of the individually measured lipids
in each lipid class in the control is set to be 1, * p,0.05 vs. the control.
doi:10.1371/journal.pone.0019423.g005
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Text S1 General lipidomics protocol and liver lipidomics
platform characteristics.
(DOC)
Figure S1 An example of a typical LC–MS chromatogram from
a mouse liver total lipid extracts in ESI
+ mode.
(TIF)
Figure S2 PCA of plasma and liver lipidomics data was applied
to differentiate the nontreated controls (n=8) and the animals
treated with rimonabant (n=8) of plasma and liver, respectively.
PCA scores plot for all plasma samples (A) and all liver samples (B)
from mean centred plus unit variance scaled data. Mouse marked
with 3733 from the controls is an outlier of the PCA model for
both the plasma lipidomics data and the liver lipidomics data.
(TIF)
Figure S3 Calibration curves for validation standard mixture
(added to samples before lipid extraction). The calibration curves
for each validation standard were determined from mouse liver
total lipid extracts. Calibration curves of LPC (19:0) at
0.5,180 mg/ml (A) and 30,180 mg/ml (B); of PC (38:0) at
2.5,450 mg/ml (C) and 150,900 mg/ml (D); of PE (30:0) at
1.5,270 mg/ml (E) and 90,540 mg/ml (F); and of TG (45:0) at
1.5,270 mg/ml (G) and 90,540 mg/ml (H).
(TIF)
Table S1 General information of 8 exogenous lipid standards
used in lipidomics analyses.
(DOC)
Table S2 The spiked concentrations of 8 exogenous lipid
standards used in lipidomics analyses and normalization strategies
used for LC-MS lipidomics data analyses.
(DOC)
Table S3 The RSD of the peak area ratios of lipids in study samples
to corresponding lipid standards calculated in all QC samples.
(DOC)
Table S4 Experimental design for method validation of liver
lipidomics profiling.
(DOC)
Table S5 Linearity (R
2) for the four lipids from the validation
mixture spiked to mouse liver samples prior to sample preparation.
(DOC)
Table S6 Intra-dayandinter-dayRSDsoftheselectedlipidsinthe
sample (peak areas were normalized to those of corresponding IS).
(DOC)
Table S7 Variation in the retention time (denoted as mean 6
S.D. min) of 8 exogenous lipid standards spiked with matrix at C4,
C6 and C8 levels for repeatability during 3-day experiments.
(DOC)
Table S8 Recoveries of four lipids from the validation standard
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